ZAGENO Secures Esteemed Placement in the 2023 ProcureTech100 Elite

Cambridge, MA, Nov 15, 2023 – (ACN Newswire) – ZAGENO Inc., the leading marketplace for life science research products, proudly announces its inclusion in the prestigious 2023 ProcureTech100. This distinguished reward is reserved for a select group of technology, data, and analytics solutions celebrated for their exceptional innovation, scalability, and transformative impact on the digital procurement landscape.

Florian Wegener, CEO of ZAGENO Inc., expressed honor in being recognized among this elite group of companies, stating, “We look forward to advancing our mission to accelerate life science research and empower procurement teams globally.”

The rigorous selection process scrutinized over 5,000 global digital solutions, evaluated by esteemed procurement leaders, technology experts, and B2B investors. Dr. Elouise Epstein, Partner at Kearney, highlighted the significance of ProcureTech100 in identifying groundbreaking solutions that drive short-term benefits and long-term value in the supply chain.

ZAGENO, the leading lab supply marketplace, provides a superior selection of high-quality products from leading suppliers, emphasizing quality and convenience. Through streamlined order tracking and billing, ZAGENO simplifies and enhances the global procurement process for biotech and pharmaceutical companies. Customers benefit from the following:

Accelerate “Phase I Clinical Trial” Timelines: ZAGENO is committed to minimizing the time it takes to reach “phase I clinical trials,” ensuring a swift and efficient progression through crucial research phases.
Enhance Scientist Productivity: By leveraging ZAGENO’s platform, scientists can experience increased efficiency and productivity, streamlining their workflow and allowing them to focus on advancing critical research initiatives.
Strengthen Supply Chain Resilience: ZAGENO is pivotal in strengthening the supply chain’s resilience for biotech and pharma companies, offering a dependable and robust procurement infrastructure that contributes to overall supply chain stability.

The announcement of the 2023 ProcureTech100 took place at the ProcureTech PIONEERS event, attracting hundreds of procurement and digital leaders. ZAGENO is honored to be featured in this exclusive list and remains committed to delivering optimal solutions for its customers.

To learn more about ProcureTech100, please visit the ProcureTech100 website.

To learn more about ZAGENO Inc., please visit the ZAGENO website.

Contact Information:
Stephanie Harold
pr@zageno.com
+1 (857) 477-8479

Envision Pharma Group Announces New AI Innovation Board and Appoints Chairwoman

HORSHAM, UK, Nov 15, 2023 – (ACN Newswire) – Envision Pharma Group (Envision), a leading global technology-enabled strategic solutions partner for the life sciences industry, unveils its AI Innovation Board and announces the appointment of Dr. Loubna Bouarfa as AI thought leader and Chairwoman of the newly established board. This strategic move underscores Envision’s global commitment to harnessing the power of AI to shape the future of the life sciences industry.

Previously serving as the CEO and founder of OKRA.ai, which was acquired by Envision in February 2023, Dr. Bouarfa revolutionized healthcare by creating AI systems that support life sciences companies to better enable the drive of personalized medicine across the globe. In this new role, she will apply her deep expertise to intertwine AI with all the services that Envision offers.

“Loubna’s appointment and the establishment of the new AI Innovation Board marks a significant step toward aligning our innovation and technology efforts to drive our strategies for our internal team, business, and partners,” shares Howard Miller, CEO of Envision Pharma Group. “We are confident this strategic move will propel Envision to new heights.”

In her new role, Dr. Bouarfa will focus on advancing AI strategy and promoting its integration across all aspects of Envision. This appointment solidifies Envision’s dedication to leveraging AI to deliver innovative, faster outcomes for the life sciences industry. In addition, Dr. Bouarfa will lead the AI Innovation Board to define and develop Envision’s AI strategy across all technology platforms, solidify thought leadership as pioneers in AI, and pilot new innovative AI applications.

Having earned the Deloitte Fast 50 Women in Leadership Award and a place on Forbes’ 50 Top Women in Tech list, Dr. Bouarfa expressed her commitment to the role, saying, “I am excited to take on this new challenge and continue driving AI innovation at Envision. We are dedicated to leading the industry in this space and delivering innovative solutions that will transform the future of life sciences. Our success will not only bring commercial benefit to clients but lead to improved patient outcomes across the globe.”

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 19 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information
Colleen Carter
Associate Director, Communications, Office of CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856

EuroEyes Celebrates Grand Opening of Flagship Clinic across from Luxury Shopping Centre, Times Square, Hong Kong

HONG KONG, Nov 13, 2023 – (ACN Newswire) – EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, HKEX: 1846) a leading global vision correction service provider, announces the Grand Opening of the Company’s Flagship Eye Clinic covering an area of more than 8,000 square feet in Hong Kong’s luxury shopping district, Times Square, Causeway Bay.

With its expert international medical team, EuroEyes Hong Kong offers the latest techniques in ophthalmic treatments and top-tier eye care through the combination of its diversified eye examination instruments and tailor-made eye treatment plans. The clinic provides treatment options for vision correction, cataracts, and other eye diseases. It is one of only four eyecare facilities in Hong Kong that provides the cutting-edge Smile Pro® treatment. As a minimally invasive treatment, the Smile Pro® treatment is among the gentlest forms of eye surgeries and EuroEyes’ preferred choice for correcting myopia. EuroEyes also offers a series of modern and safe laser eye treatments for presbyopia, a common condition typically affecting people over 45 that results in a gradual loss of the eyes’ ability to focus on nearby objects due to the natural progression of aging. The treatments yield an improved high-definition vision that enables patients to get rid of the troubles of glasses, contact lenses or reading glasses.

Replacing the high fashion brand Prada’s former flagship store, EuroEyes Hong Kong’s uniquely designed medical clinic covers two floors and has a showroom that faces Times Square’s vibrant pedestrian walking area and highly popular tourist spot. It also has an optometry center for hosting eye health lectures and different educational activities where the public can learn about various personal eye health needs.

Dr. med. Jørn S. Jørgensen, Founder, Chairman and CEO of EuroEyes, commented: “This is an exciting step for EuroEyes to establish a state-of-the-art eye clinic in the heart of Hong Kong Island’s luxury shopping district. With our highly skilled medical professionals, expansive clinic, and cutting-edge equipment, we are well-prepared to serve Hong Kong’s growing needs for premier quality eye care. The prevalence of myopia is especially on the rise due to our consistent use of digital products. As such, it is estimated that around 4.0 million or half of Hong Kong residents will be affected by myopia by 2025, according to Frost and Sullivan. Moreover, the population with presbyopia is predicted to grow from 3.3 million in 2020 to 3.6 million by 2025 while the number of cataract patients in Hong Kong is expected to grow from 0.6 million in 2020 to 0.9 million in 2025 for a CAGR of 6.9%.”

EuroEyes Group has maintained a long-term partnership with Carl Zeiss, a leading manufacturer of optical systems and optoelectronics in Germany, and is recognized as a Global Center of Excellence of Carl Zeiss Meditech AG for its technological competence. Additionally, in 2021, the Group was once again presented with the “hat trick goal” award including: the most implanted Trifocal lenses (Zeiss) worldwide in the treatment of presbyopia, the most ICL implantations in Europe in the treatment of myopia, and the most SMILE Pro laser eye operations in Europe.

Listed on the Hong Kong Stock Exchange, EuroEyes Group is one of the most profitable publicly listed eye clinics in Hong Kong and has the highest EBITDA margin and second highest net margin. In August, the Group announced record high revenue of HKD346.4 million and gross profit of HK$167.6 million for the first half of 2023, with YoY growth of 9.7% and 17.6% respectively. The strong rebound following the lifting of Covid-19 policies highlights robust demand in Europe and China for premier quality eye treatments. As a result of management’s dedication to streamlining operations, EBITDA grew 23.6% to HK$141.7 million and EBITDA margin increased to 40.9%. Furthermore, the Company performed 6,993 eye surgeries during the third quarter of 2023 ending September 30th, representing a 17% increase over the 5,967 eye surgeries performed in the same period in 2022.

Euroeyes HongKong is a member of the EuroEyes International Eye Group (EE) with flagship clinics in: Beijing, London, Berlin, Copenhagen, Düsseldorf, Frankfurt, Hamburg, Hong Kong, Munich, Shanghai, Shenzhen, and Guangzhou.

About EuroEyes International Eye Clinic Limited (1846.HK)

EuroEyes was established in 1993 and is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 30 years of experience with individualised customer care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Denmark, the PRC and the United Kingdom. The Group’s vision correction services include (i) refractive laser surgery (which includes ReLEx smile and Femto LASIK and Presbyond®); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation). For more information, please visit ir.euroeyes.hk.

EuroEyes Celebrates Grand Opening of Flagship Clinic across from Luxury Shopping Centre,Times Square, Hong Kong

HONG KONG, Nov 13, 2023 – (ACN Newswire) – EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, HKEX: 1846) a leading global vision correction service provider, announces the Grand Opening of the Company’s Flagship Eye Clinic covering an area of â€‹â€‹more than 8,000 square feet in Hong Kong’s luxury shopping district, Times Square, Causeway Bay.

About EuroEyes International Eye Clinic Limited (1846.HK)

Tenth Study Demonstrates Good Health in Vegan Dogs

WINCHESTER, ENGLAND, Nov 10, 2023 – (ACN Newswire) – Although biologically omnivores, dogs are often labelled as carnivores. Almost never are they considered vegetarians. Yet vegan pet foods (excluding any animal products) are increasingly being developed for environmental and animal welfare reasons. And now a study just published in the British Journal of Nutrition has demonstrated good health outcomes in dogs fed vegan diets. Dr Sarah Dodd and other veterinary nutritional specialists from Canada’s Ontario Veterinary College found that 31 dogs fed vegan diets for three months had health outcomes as good as 30 fed meat-based diets.

The dogs were comprehensively assessed via veterinary examinations, blood and urine tests, and X-rays. Vitamin D plays a key role in regulating bodily calcium levels, and in maintaining good bone health. It is normally sourced from animals, and the effectiveness of vegan vitamin D had been uncertain. However, Dodd’s research group showed that blood levels of vitamin D and calcium did not change in dogs fed entirely vegan diets. X-rays confirmed that bone mineral content and density were unaffected, and other health parameters were also maintained.

This is the latest among 10 studies that have now confirmed good health outcomes in dogs fed vegan diets. Some are very large-scale studies, following an explosion of recent interest in this field. In 2002, Dodd and her colleagues analysed the lifespans of 1,201 dogs, finding that dogs fed vegan diets lived 1.5 years longer, on average. Said Andrew Knight, a veterinary Professor of Animal Welfare, “That equates to around an extra decade, at the end of a human lifespan. And as well as longer lives, dogs fed vegan diets seem to enjoy better quality of life, because rates of key illnesses impacting life quality, consistently appear lower.” In 2002 Prof. Knight and colleagues also studied health outcomes in 2,536 dogs and concluded that the healthiest and least hazardous diets for dogs were nutritionally sound vegan diets.

Even cats appear to benefit from vegan diets, provided these are nutritionally-sound. At least three studies have confirmed positive health findings in cats. A 2023 study of 1,369 cats by Knight and colleagues calculated reductions in risks of a broad range of illness indicators, for cats fed vegan diets. Their detailed analysis of feeding behaviour of 2,308 dogs and 1,135 cats also found that average pets appeared to enjoy vegan meals, as much as those based on meat.

Knight commented that these new studies had opened the door to major environmental benefits offered by vegan pet food. His 2023 study calculated that vegan pet food could save enormous quantities of greenhouse gases, land, and water and that resultant food energy savings could feed billions of additional people globally. Another landmark study also recently identified major climate benefits associated with plant-based diets.

However, Knight cautioned that, “to safeguard the health of our pets, it is important we feed only commercial vegan pet foods labelled as nutritionally complete, produced by reputable companies with good standards.”

Contact Information
Andrew Knight,
Veterinary Professor of Animal Welfare
andrew.knight@winchester.ac.uk

Indonesia’s ITS Launches 7 MedTech Devices Based on Various Integrated Technologies

SURABAYA, Indonesia, Nov 9, 2023 – (ACN Newswire) – Sepuluh Nopember Institute of Technology (ITS), a leading university in Indonesia, with PT Tekno Sains Medika and PT Bina Makmur Abadi, has developed seven medical devices using integrated digital technologies, in a significant boost to the country’s nascent MedTech industry.

The seven devices use integrated 3D design and digital fabrication technology. Through fabrication technology, products can be customized and made based on consumer request. It is expected that the use of this technology can help speed up the handling of medical cases, said Djoko Kuswanto, ITS lecturer and medical equipment inventor.

ITS launches seven medical technology devices using integrated 3D design and digital fabrication technology – a boost to the country’s MedTech industry [IMAGE: ITS].

The new products include AMO3D, a 3D-printed implant mold based on patient data; GUO3D, a 3D-printed work support tool; and PRO3D, a 3D-printed body protective device made using patient-specific scans. These tools are the only ones in Indonesia that combine innovation and digital technology for use in healthcare settings.

ITS has also created products called HUMA3D in the form of a mannequin, and TSM.Bones, a replica of human bones for educational purposes and clinical training for aspiring medical professionals.

The final products are RiseHand, a tool that assists patients with amputated fingers in grasping objects, and Surgical Instrument, a range of tools for surgical operations, including scissors, knives, and tweezers.

These medtech products, which were launched at the 35th Hospital Expo, Jakarta Convention Center on October 18 have been used by several hospitals and universities in Indonesia, and hundreds of units of the devices have been ordered. So the quality of these products is no less competitive comparing with products from developed countries, Kuswanto said.

Bambang Pramujati, ITS Deputy Rector, said: The launch of these medtech devices is proof of ITS’ commitment to developing technology in the health sector. The large volume of imported medical equipment and the rapid development of technology prompted ITS to develop the medical equipment by increasing the domestic component level to above 40 percent.

Besides collaborating with Airlangga University Hospital (RSUA) for the research and trials phase, the development of the new medical devices also involved the use of locally sourced components and the support of digital technology, said Pramujati.

Digital 3D printing technology, artificial intelligence (AI), as well as augmented reality (AR) and virtual reality (VR), can be used to improve health facilities in Indonesia, Pramujati said.

Nike Besta Sari, Director of PT Tekno Sains Medika, said: The price of the products is lower compared to other similar products. For example, HUMA3D is being sold for just under Rp50 million (around US$3,200), which makes it cheaper compared to similar products that cost hundreds of millions of rupiah.

Using locally-made components, the new devices are produced on a pre-order system. Sales pricing is less than that of imported products, but does not reduce product quality, Sari said, adding that the company would be holding development workshops regarding the healthcare tools at various locations throughout Indonesia.

By Yashinta Difa Pramudyani, Edit by Anton Santoso, COPYRIGHT (c) ANTARA 2023

BioMed X Launches a New Call for Application in Autoimmune Disease Research

HEIDELBERG, Germany, Nov 7, 2023 – (ACN Newswire) – BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.

Current therapeutic strategies for autoimmune diseases primarily focus on broadly suppressing the immune response, with significant side effects. More importantly, none of these treatments address one of the root causes of the disease, the autoreactive plasma cells that produce antibodies targeting self-antigens. By exploring the deep biology of human autoreactive plasma cells to identify biomarkers that distinguish them from their physiological counterparts, this project aims to identify new therapeutic strategies to selectively eliminate these cells in patients suffering from autoimmune diseases.

“Immunology – including autoimmunity – is one of our R&D focus areas at our BioMed X Institutes in Heidelberg, New Haven, and our XSeed Labs in Ridgefield. Currently, we are hosting five immunology research teams at different stages of development. We are excited to extend our immunology research capabilities with this new project in the field of autoreactive plasma cells,” explains Christian Tidona, Founder and Managing Director of the BioMed X Institute.

This new research group will be located at the BioMed X Institute in Heidelberg, Germany. Each BioMed X project is a collaboration with a leading pharmaceutical company. To learn more about this project and how to apply, visit the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C02. The deadline for applying is January 7, 2023.

About BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information

Flavia-Bianca Cristian, Recruiting & Communications Manager, fbc@bio.mx +49 6221 426 11 706

Acrometa Group Signs MOU for Sand Concession, Opening New Business Opportunities in the Region

SINGAPORE, Nov 6, 2023 – (ACN Newswire) – ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), today announced that the Company has signed a Memorandum of Understanding (“MOU”) to pursue new business opportunities in Indonesia.

A non-binding non-exclusive MOU was signed between ACROMETA and PT. Swadaya Buana Makmur (“PTSBM”) for the supply of high-grade silica sand from West Kalimantan, Indonesia.

Subject to relevant export approvals, a new subsidiary set-up for the proposed business will target to purchase and PTSBM will target to supply an annual offtake of up to 1,000,000 tonnes of Low Iron Silica Sand with a guaranteed quality of at least 99.5% SIO2 at prices and payment terms in line with market conditions. Both parties are set to enter into definitive Offtake/Purchase Agreements with a target for the Newco to commence its first trade by 15 January 2024.

Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman said, “The MOU with PTSBM is a synergistic opportunity given the Group’s deep expertise in specialist engineering services as we seek to broaden the Group’s revenue stream. ACROMETA will continue to capture new business opportunities to grow and create shareholder value for its investors.”

Trend for the demand for high-grade 99.5% purity silica sand is increasing and are used in the manufacture of precision glass instruments, ophthalmic lenses and LCD screens required by many industries such as the biotechnology, electronics, and pharmaceutical industries. In construction, it is the main structural component in several construction products such as flooring, mortars, cement, roofing shingles, and asphalt. The Group is currently speaking with potential international buyers before entering into formal offtake agreements with PTSBM.

[1] Market Prices fluctuate according to prevailing market conditions.

About ACROMETA Group Limited (SGX Stock Code:43F)

ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.

The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.

The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.

The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.

Media and Analysts Contact:
ACROMETA Group Limited
Ms. Cheah Lai Min
Chief Financial Officer
Tel: +65 6415 0574
Email: laimin.cheah@acrometa.com

Waterbrooks Consultants Pte Ltd
Mr. Wayne Koo
Tel: +65 6958 8008 / +65 9338 8166
Email: wayne.koo@waterbrooks.com.sg Email: query@waterbrooks.com.sg

This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange

Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com

SAFE Fertility Group Plc (SAFE) enjoys trading debut on SET

BANGKOK, Nov 2, 2023 – (ACN Newswire) – SAFE Fertility Group Plc, or SAFE, a comprehensive fertility clinic operator, made its debut on the Stock Exchange of Thailand (SET). The company has a strategy to build on its strengths in fertility treatment to achieve sustainable growth and become a leader in fertility treatment, genetic diagnosis of embryos, and wellness in Asia. In the first half of this year, the company reported strong earnings with net profit of over THB 87 million.

Dr. Wiwat Quangkananurug, a medical specialist in fertility treatment with assisted reproductive technology, as the Chief Executive Officer of SAFE, reported that the company’s shares were listed on the SET on November 2, 2023, under the service industry. This was after the company successfully offered 76,748,600 new shares to the public for the first time (IPO) at THB 21 per share. This is a major step for SAFE to support the company’s plans to expand its fertility treatment services and genetic laboratories to be more comprehensive. This will help fulfill the dreams of infertile people to have the opportunity to have the children they desire. SAFE will also help drive Thailand to be a destination for infertile people from around the world (Fertility Tourism), in line with the government’s policy to develop Thailand into an international health hub to drive the economy in the future.

In addition, the company has a strategy to drive the business to become a leader in fertility treatment, genetic diagnosis of embryos, and wellness in Asia. This will be achieved through the expansion of fertility clinics and fertility laboratories to partner hospitals with a nationwide network or to partner healthcare facilities in locations with economic and tourism potential. This will be done through commercial partnerships, joint ventures, and mergers and acquisitions. The company will also use modern and effective treatment technologies and continuously develop its service staff to promote its leadership. In addition, the company will communicate and build the “SAFE FERTILITY” brand as a leader in fertility treatment and embryo genetic diagnosis in Asia in a more aggressive way, such as through offline and online channels to consumers in Thailand and abroad, and through digital marketing. The company also plans to expand into other related businesses.

SAFE plans to use the proceeds from the fundraising to create sustainable growth potential in the future. In the near term, the company will relocate its Ramindra branch to a space in the Golf Channel Center golf driving range project on Ramindra Road. This will make it more convenient for customers and provide more comprehensive services, such as a modern and spacious genetics laboratory for the company’s scientists. The company expects to invest approximately THB 100 million in this project. The company is also considering the opportunity to invest in laboratories in private and government hospitals, and to partner with private hospitals in Thailand and abroad in the form of joint ventures.

The company’s operating results for the years 2023-2025 were THB 529.77 million, THB 561.96 million, and THB 729.32 million, respectively. The net profit for the same periods was THB 42.16 million, THB 78.23 million, and THB 161.73 million, respectively. For the first six months of 2023, the company had total revenue of THB 409.84 million, an increase of 9.4% from the same period of the previous year. The net profit was THB 87.4 million, a decrease of 3.89% from the same period of the previous year. The slight decrease in net profit was due to expenses incurred in preparation for the company’s listing on the stock exchange, which are one-time expenses.

“We are confident that SAFE will grow by leaps and bounds from its strong financial foundation and become a leader in fertility treatment, embryo genetic diagnosis, and wellness in Asia. We will help fulfill the dreams of infertile people by focusing on providing world-class services that are committed to patient safety with innovative and modern technologies,” said the CEO of SAFE.

Darin Kanjana, CEO of Optasia Capital, as the financial advisor, said that SAFE is a company with high business growth potential in the overall global fertility treatment market, which is growing significantly. It will be a Growth Stock that will generate good returns for investors. This is due to the company’s distinctive business model, which is mutually beneficial and will drive the company’s sustainable growth. The company also provides integrated full-service for fertility clinics that are certified to meet international standards for reproductive services.

She added that the company has 5 branches in key locations, has good relationships with hospitals, obstetrics and gynecology clinics, fertility centers, etc., and is well-known for treating infertile foreigners from countries such as China, India, Myanmar, Vietnam, Singapore, and Japan.

Pichet Sitthi-Amnuai, CEO of Bualuang Securities, as the underwriter, said that the IPO offering of SAFE was a total of 76.75 million shares at a price of THB 21 per share, with a total offering value of THB 1,611.72 million. It was well-received by both leading institutional investors and retail investors. This is because investors are confident in the business potential of SAFE, which is a leader in fertility treatment and is in an industry with high growth potential. The investors are also confident that the fundraising will strengthen the company’s financial position to expand its business as planned.

Furthermore, SAFE is committed to social activities. The company will consider the interests of stakeholders in various dimensions, including the company, employees, customers, the public, society, and various organizations. The company has projects to donate money to schools in need, donate medical equipment to hospitals, and donate THB 100 of service fees for every Qualify test to charity. Mr. Pichet is confident that SAFE will be a quality stock in the Thai capital market.

Visit: https://www.safefertilitygroup.com/en/home (SET: SAFE; SET: SAFE-R; SET: SAFE/F)

This press release is distributed by MT Multimedia Co., Ltd. for SAFE Fertility Group Pcl.
Please contact: Wasana Wongsiri (Jeab), Tel: +66 84-359-0659 or +66 2-612-2081 x131, Email: wasana.w@mtmultimedia.co

DC Healthcare Unveils Innovative Skincare Range ‘newB’ Under Subsidiary Ten Doctors Sdn Bhd

KUALA LUMPUR, Nov 1, 2023 – (ACN Newswire) – DC Healthcare Holdings Berhad (“DC Healthcare” or the “Company”), an aesthetic medical services provider specialising in the provision of non-invasive and minimally invasive procedures, announced today the launch of ‘newB,’ a state-of-the-art skincare line developed by its subsidiary, Ten Doctors Sdn Bhd (10DRS). The new range is segmented into two categories: newB Premium Ageless and newB Premium Hydration, both formulated to set new standards in skincare efficacy.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare

Engineered with the revolutionary ingredient DiamondC60™, the newB Premium Ageless range delivers potent anti-ageing benefits. This ground-breaking ingredient contains Japan Quality Fullerene “The First Natural Fullerene in Malaysia directly from Japan”, exhibits superior anti-oxidative performance compared to traditional anti-ageing components like Vitamin C.

In parallel, the newB Premium Hydration collection is empowered by the innovative 7HA Boost Complex. This advanced formulation incorporates seven distinct molecular sizes of hyaluronic acid and FUCOGEL®, ensuring ultimate water-boost for lasting healthy, soft and plump skin.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare, stated, “The launch of newB is a strategic move in diversifying our healthcare portfolio. Our skincare products are developed with scientific precision, catering to the evolving skincare needs of our clientele. These new product lines not only contribute to our revenue streams but also enhance our reputation as a comprehensive healthcare provider. We are particularly encouraged by the commercial applications of DiamondC60™, an ingredient that we believe will set new industry standards.”

Amid projections for the Malaysian aesthetic medicine market to register a CAGR of 18.8% from 2021 to 2027, the introduction of newB resonates with DC Healthcare’s commitment to innovation and excellence. The new skincare ranges are available for purchase through multiple online platforms, including Shopee, Lazada, TikTok shop, and Watsons Malaysia Online Store.

Moving forward, DC Healthcare will continue to focus on its core business, which includes aesthetic services and innovative healthcare solutions like newB. The Company plans to expand existing clinics, invest in cutting-edge technology, and fortify its team of medical professionals to capitalise on the growth opportunities presented by the aesthetic medicine market.

As at 31 October 2023, the share price of DC Healthcare stands at 0.52 sen per share, reflecting a market capitalisation of RM518.1 million.

For more information, please visit this LINK.